<Header>
<FileStats>
    <FileName>20161130_10-Q-A_edgar_data_1514946_0001078782-16-003875_1.txt</FileName>
    <GrossFileSize>2298047</GrossFileSize>
    <NetFileSize>10929</NetFileSize>
    <ASCII_Embedded_Chars>215606</ASCII_Embedded_Chars>
    <HTML_Chars>269115</HTML_Chars>
    <XBRL_Chars>981377</XBRL_Chars>
    <XML_Chars>797618</XML_Chars>
    <N_Tables>1</N_Tables>
    <N_Exhibits>8</N_Exhibits>
</FileStats>
<SEC-Header>
0001078782-16-003875.hdr.sgml : 20161130
<ACCEPTANCE-DATETIME>20161129184014
ACCESSION NUMBER:		0001078782-16-003875
CONFORMED SUBMISSION TYPE:	10-Q/A
PUBLIC DOCUMENT COUNT:		64
CONFORMED PERIOD OF REPORT:	20160930
FILED AS OF DATE:		20161130
DATE AS OF CHANGE:		20161129

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AXIM BIOTECHNOLOGIES, INC.
		CENTRAL INDEX KEY:			0001514946
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				274092986
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-54296
		FILM NUMBER:		162023734

	BUSINESS ADDRESS:	
		STREET 1:		18 E. 50TH STREET
		STREET 2:		5TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		(212) 751-0001

	MAIL ADDRESS:	
		STREET 1:		18 E. 50TH STREET
		STREET 2:		5TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AXIM INTERNATIONAL INC.
		DATE OF NAME CHANGE:	20110309

</SEC-Header>
</Header>

 0001078782-16-003875.txt : 20161130

10-Q/A
 1
 f10qa093016_10qz.htm
 FORM 10-Q/A AMENDED QUARTERLY REPORT

Form 10-Q/A Amended Quarterly Report 

FORM 10-Q  
  (Amendment #1)  
   
 U.S. SECURITIES AND EXCHANGE COMMISSION 
 Washington, D.C. 20549 
   
    X   .  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 
   
  For the quarterly period ended September 30, 2016  
   
 OR 
          .  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 
   
 For the transition period from ________ to ________ 
   
 Commission file number 000-54296 
   
  AXIM Biotechnologies, Inc.  
 (Exact name of registrant as specified in its charter) 

Nevada  
          27-4029386  
  
   (State or other jurisdiction  
 of incorporation or organization) 
        (I.R.S. Employer  
 Identification Number) 

18 E 50th St 5th Floor, New York, NY 10022   
 (Address of principal executive offices) 
   
   (212) 751-0001   
 (Registrant s telephone number, including area code) 
 ________________________________________________ 
 (Former name, former address and former fiscal year, if changed since last report) 
   
 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes   X   .  
   
 Indicate by check mark whether registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). No   X   .  
   
 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of  large accelerated filer,   accelerated filer  and  smaller reporting company  in Rule 12b-2 of the Exchange Act. (Check one): 

Large accelerated filer         .  
   Accelerated filer         .  
   Non-accelerated filer         .  
 (Do not check if a smaller reporting company) 
   Smaller reporting company   X   .  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). No   X   .  
   
 APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY 
 PROCEEDINGS DURING THE PRECEDING FIVE YEARS 
   
 Indicate by check mark whether the registrant filed all documents and reports required to be filed by Section 12, 13, or 15(d) of the Exchange Act of 1934 after the distribution of securities under a plan confirmed by a court. Yes         .  No         .  
   
 APPLICABLE ONLY TO CORPORATE ISSUERS 
   
 Indicate the number of shares outstanding of each of the issuer s classes of common stock, as of the latest practicable date: 51,492,659 shares of common stock, par value $0.0001 per share, outstanding as of November 21, 2016.       

_____________________________________________________________________________________________  
   
  Explanatory Note  
   
 This Amendment No. 1 to the Quarterly Report on Form 10-Q (the  Form 10-Q ) for the period ended September 30, 2016, is to furnish Exhibit 101 to the Form 10-Q in accordance with Rule 405 of Regulation S-T.  Exhibit 101 to the Form 10-Q provides the financial statements and related notes from the Form 10-Q formatted in XBRL (eXtensible Business Reporting Language).  No other changes have been made to the Form 10-Q. This Amendment No. 1 to the Form 10-Q speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-Q.  Pursuant to Rule 406T of Regulation S-T, the interactive data files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections. 
  _____________________________________________________________________________________________  

2 

Item 6. Exhibits.  

Statements  

Condensed Consolidated Balance Sheets as of September 30, 2016 (unaudited) and December 31, 2015. 

Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2016 and 2015 (unaudited) 

Condensed Consolidated Statements of Changes in Shareholders' Deficit for the nine months ended September 30, 2016 (unaudited) 

Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2016 and 2015 (unaudited) 

Notes to Condensed Consolidated Financial Statements (unaudited) 

Schedules  

All schedules are omitted because they are not applicable or the required information is shown in the Financial Statements or notes thereto. 

3 

SIGNATURES  
   
 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. 

AXIM BIOTECHNOLOGIES, INC.  

Dated: November 29, 2016 
   By: 
    /s/ Dr. George Anastassov  

Dr. George Anastassov 

President and Director 
 Principal Executive Officer 

Dated: November 29, 2016 
   By: 
    /s/ Robert Malasek  

Robert Malasek 

Principal Financial Officer 

4 

<EX-31.1>
 2
 f10qa093016_ex31z1.htm
 EXHIBIT 31.1 SECTION 302 CERTIFICATION

Exhibit 31.1 Section 302 Certification 

Exhibit 31.1  
  
I, Dr. George Anastassov, certify that: 
   
 1. 
 I have reviewed this Report on Form 10-Q (A/1) for AXIM Biotechnologies, Inc.; 
   
 2. 
 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 
   
 3. 
 Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 
   
 4. 
 The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: 
   
 a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 
   
 b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; 
   
 c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 
   
 d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 
   
 5. 
 The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):  
   
 a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and  
   
 b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. 
   
 Date:  November 29, 2016 

/s/ Dr. George Anastassov   
 Dr. George Anastassov 
 Chief Executive Officer 

</EX-31.1>

<EX-32.1>
 3
 f10qa093016_ex32z1.htm
 EXHIBIT 32.1 SECTION 906 CERTIFICATION

Exhibit 32.1 Section 906 Certification 

Exhibit 32.1  

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002  
   
 In connection with the Report of AXIM Biotechnologies, Inc., a Nevada Corporation, (the  Company ) on Form 10-Q (A/1) for the Quarter ended September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the  Report ), the undersigned certify the following pursuant to Section 18, U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002: 

1.   
   The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and 

2.   
   The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company. 

/s/ Robert Malasek   
 Robert Malasek 
 Chief Financial Officer 
 Principal Accounting Officer 
   
 November 29, 2016 

</EX-32.1>

<EX-101.CAL>
 4
 axim-20160930_cal.xml
 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

</EX-101.CAL>

<EX-101.DEF>
 5
 axim-20160930_def.xml
 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

</EX-101.DEF>

<EX-101.INS>
 6
 axim-20160930.xml
 XBRL INSTANCE DOCUMENT

</EX-101.INS>

<EX-101.LAB>
 7
 axim-20160930_lab.xml
 XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT

</EX-101.LAB>

<EX-101.PRE>
 8
 axim-20160930_pre.xml
 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

</EX-101.PRE>

<EX-101.SCH>
 9
 axim-20160930.xsd
 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT

</EX-101.SCH>

